RxSight Inc (RXST)
44.16
-0.49
(-1.10%)
USD |
NASDAQ |
Nov 14, 16:00
44.19
+0.03
(+0.07%)
After-Hours: 20:00
RxSight Research and Development Expense (Quarterly): 8.838M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 8.838M |
| June 30, 2024 | 8.291M |
| March 31, 2024 | 8.031M |
| December 31, 2023 | 7.341M |
| September 30, 2023 | 7.101M |
| June 30, 2023 | 7.401M |
| March 31, 2023 | 7.208M |
| December 31, 2022 | 6.681M |
| September 30, 2022 | 6.388M |
| June 30, 2022 | 6.192M |
| Date | Value |
|---|---|
| March 31, 2022 | 6.719M |
| December 31, 2021 | 5.916M |
| September 30, 2021 | 5.377M |
| June 30, 2021 | 6.563M |
| March 31, 2021 | 6.643M |
| December 31, 2020 | 5.272M |
| September 30, 2020 | 5.801M |
| June 30, 2020 | 5.084M |
| March 31, 2020 | 5.777M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
5.084M
Minimum
Jun 2020
8.838M
Maximum
Sep 2024
6.664M
Average
6.643M
Median
Mar 2021
Research and Development Expense (Quarterly) Benchmarks
| Tandem Diabetes Care Inc | 51.11M |
| Perspective Therapeutics Inc | 9.275M |
| Retractable Technologies Inc | 0.1991M |
| Xtant Medical Holdings Inc | 0.636M |
| Catheter Precision Inc | 0.081M |